Long-Term Psoriasis Management in Older and Medically Complex Patients: Key Considerations for Tildrakizumab

Updated:Nov 18, 2026

About this video

In this installment of Discourses in Dermatology, Dawn Merritt, DO, reviews a recently published expert consensus on the long-term management of psoriasis in older and medically complex patients, with a focus on the safety, efficacy, and durability of tildrakizumab. Distilling the publication's 10 consensus statements into 3 overarching themes, Dr Merritt examines clinical trial and real-world evidence supporting tildrakizumab and discusses treatment considerations that may influence long-term disease control in patients with multiple comorbidities.

Psoriasis management frequently extends beyond skin clearance, particularly in patients with cardiovascular disease, diabetes, obesity, and other chronic conditions. Older patients may also face challenges related to polypharmacy, multiple specialist appointments, and treatment access. These factors can complicate systemic treatment selection and underscore the importance of considering both clinical outcomes and the feasibility of maintaining therapy over time.

Efficacy and durability: Understanding the treatment response over time

The first theme centers on the efficacy and durability of tildrakizumab, including the potential for continued improvement beyond initial treatment assessments.

In the pivotal reSURFACE trials, approximately 60% to 66% of patients receiving tildrakizumab achieved a 75% improvement in Psoriasis Area and Severity Index (PASI 75) at week 12, compared with approximately 6% of patients receiving placebo. Dr Merritt highlights the continued improvement observed through week 28, particularly for higher thresholds of skin clearance, including PASI 90 and PASI 100.

These findings are relevant when evaluating patients who demonstrate an initial response but have not yet achieved their desired level of clearance. Dr Merritt notes that an incomplete response at week 12 does not necessarily indicate treatment failure. For patients who are tolerating therapy and demonstrating improvement, continued treatment with reassessment closer to week 28 may be a consideration.

Long-term extension data further demonstrated sustained disease control through 5 years among patients who responded to treatment. Improvements were also observed in high-impact areas, including the scalp and nails, where psoriasis can substantially affect daily activities and quality of life.

Together, these findings highlight the importance of evaluating not only the initial onset of response but also the potential for continued improvement and sustained disease control.

Safety and efficacy in older patients and those with comorbidities

The second theme addresses the evidence supporting tildrakizumab in patients whose age, comorbidities, or concomitant medications may complicate systemic treatment decisions.

Dr Merritt notes that the cardiometabolic burden associated with psoriasis can influence treatment selection, particularly among patients with multiple chronic conditions. Across clinical trials and long-term extension studies, tildrakizumab demonstrated a consistent safety profile, with low reported rates of serious adverse events, serious infections, and major adverse cardiovascular events. No new safety signals were identified through 5 years of follow-up.

Although older and medically complex patients are often underrepresented in clinical trials, Dr Merritt highlights additional evidence evaluating tildrakizumab in these populations. A pooled analysis of patients older than 65 years demonstrated maintained efficacy despite a greater prevalence of comorbidities and concomitant medication use. Real-world studies have also reported effectiveness in frail older adults and patients with metabolic syndrome.

Dr Merritt emphasizes that advanced age or the presence of multiple comorbidities should not automatically preclude consideration of biologic treatment. Rather, these characteristics reinforce the importance of individualized treatment selection, including assessment of the patient's overall medical history, concomitant therapies, and treatment goals.

Treatment administration, adherence, and long-term persistence

The third theme focuses on factors that may influence a patient's ability to remain on treatment, including dosing frequency, administration requirements, and insurance coverage.

Dr Merritt reviews real-world evidence demonstrating favorable adherence and treatment persistence with tildrakizumab. In one retrospective analysis, treatment persistence was longer with tildrakizumab than with several other IL-23 inhibitors. Although persistence is influenced by multiple factors, she identifies the dosing schedule and health care professional–administered model as potentially relevant considerations.

Following initial doses at weeks 0 and 4, tildrakizumab is administered every 12 weeks. This relatively infrequent maintenance schedule may be advantageous for patients managing multiple medications and treatment-related responsibilities.

In addition, administration by a health care professional provides opportunities for scheduled follow-up and oversight of treatment delivery. For some older patients, particularly those who may have difficulty managing self-administered medications, this model may help support treatment continuity.

Insurance coverage is another consideration. Tildrakizumab may be covered under Medicare Part B for eligible patients, offering an alternative coverage pathway for individuals who encounter challenges obtaining biologic therapy through their prescription drug benefits.

Dr Merritt emphasizes that these logistical considerations are relevant to long-term psoriasis management. Treatment efficacy alone does not determine outcomes; access, adherence, and the ability to sustain therapy are also important components of individualized care.

For a comprehensive review of the evidence, including all 10 consensus statements, readers can access the full publication in Dermatology Online Journal.

Key Takeaways

Efficacy may continue to improve beyond week 12: Clinical trial data demonstrate continued improvement with tildrakizumab through week 28, while long-term extension findings support sustained disease control through 5 years among treatment responders

Evidence extends to older and medically complex populations: Pooled analyses and real-world studies support the effectiveness of tildrakizumab in older adults and patients with cardiometabolic comorbidities, alongside a consistent long-term safety profile

Treatment characteristics may influence continuity of care: Every-12-week maintenance dosing, health care professional administration, and potential Medicare Part B coverage are considerations that may support treatment access and persistence in selected patients

Individualized assessment remains essential: Age, comorbidities, concomitant medications, treatment goals, and practical barriers to care should all inform systemic treatment selection